DeciBio Consulting (“DeciBio”), a precision medicine-focused strategy consulting and market intelligence firm, launched the DeciBio Market Intelligence Portal. The portal brings DeciBio’s Market Reports, DxBooks lab survey databases, Oncology Genomics Trackers, and Transcript Database into one subscription platform. It also introduces DeciChat, an AI assistant that performs cross-product querying and synthesis. Life science tools, diagnostics, and biopharma teams can ask a question and receive an answer drawn from across DeciBio’s research, with citations to the source data.

“Precision medicine is moving faster than traditional market research can track. And decisions that once took months of analysis now need to be made in weeks,” said Rebecca Burnham, PhD, Head of DeciBio’s Market Reports Division. “The Market Intelligence Portal and DeciChat give our clients direct access to the primary research that drives those decisions, in a form they can act on right away.”

DeciChat: One Question, Every Source

DeciChat helps teams get evidence-backed answers to the market questions behind their most important decisions, from sizing an opportunity to prioritizing markets or evaluating partners. Its AI agents search proprietary data from DeciBio’s precision medicine experts, then synthesize the findings into a single response. Each answer links back to the underlying report, dataset, or transcript, so teams can verify the numbers and insights and build on them in their own analyses.

“General-purpose AI tools are only as good as what they can find, and most precision medicine market data isn’t public,” said Andrew Stiegler, PhD, Head of DeciBio’s DxBooks Division. “DeciChat’s agents work directly on our private survey data, forecasts, and interview transcripts. Automated pipelines mean every new DxBook release, tracker update, and transcript is searchable as soon as the research is completed.”

What’s Included in the Market Intelligence Portal

The Market Intelligence Portal integrates DeciChat and all of DeciBio’s proprietary data products, including:

• Global Market Reports: Comprehensive market assessments with market sizing, segmentation, and 5-year forecasts, plus competitive analysis and assessments of key players, technologies, drivers, and moderators. Report topics span life science tools and diagnostics, including Digital & Computational Pathology, Oncology Liquid Biopsy, Next-Generation Sequencing, Spatial Biology, Single Cell Analysis, Proteomics Tools, Clinical Oncology Biomarker Testing, Blood-Based Testing in Neurodegenerative Diseases, Bioprocessing, Cell Therapy R&D and Manufacturing, Pharma Real-World Data & Evidence, and more.
• Snapshot Reports: Qualitative deep dives on emerging sub-segments, such as Pharma CDx Development & Commercialization, Biopharma’s Use of AI in Drug Discovery, and Precision Medicine Opportunities in Women’s Health.
• DxBooks: Databases built from annual surveys of clinical labs:
  • NGS DxBook: Panel testing, sample types, volumes, and reimbursement across 275 US and EU labs.
  • Infectious Disease DxBook: Testing settings, assays, and vendor selection for 30 analytes across 1,000 US clinical labs.
  • Digital Pathology DxBook: Scanner and IMS usage, algorithm integration, and vendor satisfaction across 400 US and EU labs.
• Oncology Genomics Trackers: Interactive dashboards tracking oncology genomic testing across 100 US labs (quarterly) and EU labs (semiannually), characterizing the use of genomic profiling, MRD / recurrence monitoring, and treatment response monitoring.
• Transcript Database: 450+ searchable expert interviews with stakeholders across large and small biopharma, academic medical centers, community hospitals, reference labs, CROs, and diagnostics companies.